COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES

This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of adminestering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane derivative, a platinium coordination complex selected from the group consisting of carboplatin, tetraplatin, and topotecan, a nucleoside analog selected from the group consisting of gemcitabine, hydrochloride and 5-FU, an anthracycline, a topoisomerase selected from the group consisting of etoposide, teniposide, amsacrine, topotecan and CamptosarÚ, an aromatase inhibitor; and (ii) a therapeutically effective amount of an isothiazole derivative. The combinations of the present invention may optionally include an anti-hypertensive agent. This invention also relates to pharmaceutical compositions useful in the treatment of hyperproliferative diseases in mammals, containing such combinations. The present invention also relates to kits having a first compartment with a compound of formula 1 and a second compartment containing a taxane derivative, a platinum coordination complex, a nucleoside analog, an anthracycline, a topoisomerase inhibitor, or an aromatase inhibitor and a third compartment containing an anti-hypersensitive agent. L'invention concerne un procédé de traitement de maladies hyperprolifératives. Elle concerne, plus particulièrement, un procédé de traitement de maladies hyperprolifératives, telles que le cancer, consistant à administrer à un mammifère, nécessitant un tel traitement, soit simultanément, soit séquentiellement, (I) une quantité, efficace sur le plan thérapeutique, d'un dérivé de taxane, d'un complexe de coordination du platine sélectionné parmi le groupe comprenant des complexes carboplatine, tétraplatine, et topotécane, d'un analogue de nucléoside sélectionné parmi le groupe d'analogues comprenant l'hydrochlorure de gemcitabine ou le 5-fluoro-uracile, d'une anthracycline, d'un inhibiteur de topoisomérase sélectionné parmi le groupe comprenant étoposide, téniposide, amsacrine, topotécane et Camptosar